Unveiling the Molecular Mechanisms Linking Osteoarthritis and Alzheimer's disease: Shared Pathways, Mechanisms and Breakthrough Prospects

Elvira Miller^*
*Correspondence: Elvira Miller, Department of Internal Medicine, University of Sumatera Utara, Medan, Indonesia, Email:

Introduction

Osteoarthritis (OA) and Alzheimer’s Disease (AD) are prevalent agerelated disorders that significantly impact the quality of life for millions worldwide. Despite affecting distinct anatomical systems, recent research has unveiled intriguing connections between OA and AD at the molecular level. This article explores the shared pathways, mechanisms and breakthrough prospects linking these seemingly disparate conditions [1]. Both OA and AD involve chronic inflammation as a central feature. In OA, inflammation arises primarily from cartilage degradation and joint damage, while in AD, neuroinflammation is prominent due to the accumulation of amyloid-beta (Aβ) plaques and tau protein tangles. Shared inflammatory mediators such as cytokines (e.g., TNF-α, IL-1β) and chemokines perpetuate a pro-inflammatory environment, contributing to disease progression in both conditions. Oxidative stress is a common denominator in OA and AD pathogenesis. Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) induce cellular damage, exacerbating cartilage degradation in OA and neuronal dysfunction in AD. Mitochondrial dysfunction, impaired antioxidant defense mechanisms and lipid peroxidation are shared consequences of oxidative stress, linking the two diseases mechanistically [2]. Autophagy, a cellular process responsible for degrading damaged organelles and proteins, is dysregulated in both OA and AD. Impaired autophagic flux contributes to the accumulation of protein aggregates, such as Aβ in AD and misfolded proteins in OA. Shared regulators of autophagy, including mTOR and AMPK signaling pathways, highlight common molecular pathways underlying disease pathology.

Description

Cellular senescence and apoptosis play pivotal roles in OA and AD progression. Senescent chondrocytes in OA joints exhibit altered secretory profiles, contributing to inflammation and tissue degradation. Similarly, neuronal apoptosis and senescence are prominent features in AD brains, leading to cognitive decline [3]. Shared pathways involving p53, NF-KB and Bcl-2 family proteins contribute to cell fate decisions in both conditions. Identifying shared molecular pathways opens avenues for developing targeted therapies with broad applicability across OA and AD. Anti-inflammatory agents, antioxidants and modulators of autophagy represent promising candidates for disease-modifying interventions. Multi-modal approaches targeting multiple pathways simultaneously may offer synergistic benefits in managing both conditions. Personalized medicine approaches leveraging genetic, epigenetic and biomarker data hold potential for stratifying patients based on disease severity, progression and treatment response. Precision targeting of specific molecular subtypes within OA and AD cohorts can optimize therapeutic outcomes while minimizing adverse effects. Drug repurposing presents a costeffective strategy for accelerating therapeutic development in OA and AD [4]. Compounds with established safety profiles targeting shared pathways, such as NSAIDs, statins and autophagy modulators, can be repurposed for dual indication treatment, providing immediate clinical benefits to patients [5].

Conclusion

In conclusion, the intricate interplay of shared molecular pathways underscores the surprising connection between OA and AD. Insights gained from elucidating these common mechanisms offer unprecedented opportunities for developing innovative therapies and advancing precision medicine strategies. By embracing a holistic approach that addresses the converging pathogenic processes, we can strive towards more effective management and prevention of these debilitating age-related diseases.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Hardy, John A. and Gerald A. Higgins. “Alzheimer's disease: The amyloid cascade hypothesis.”Sci256

   Google Scholar, Crossref, Indexed at

2. Selkoe, Dennis J. “Translating cell biology into therapeutic advances in Alzheimer's disease.”Nat399 (1999): A23-A31.

   Google Scholar, Crossref, Indexed at

3. Lane, Christopher A., John Hardy and Jonathan M. Schott. “Alzheimer's disease.”Eur Neurol25 (2018): 59-70.

   Google Scholar, Crossref, Indexed at

4. Heneka, Michael T., Monica J. Carson, Joseph El Khoury and Gary E. Landreth, et al. “Neuroinflammation in Alzheimer's disease.”Lancet Neurol 14 (2015): 388-405.

   Google Scholar, Crossref, Indexed at

5. Rajesh, Yetirajam and Thirumala-Devi Kanneganti. “Innate immune cell death in neuroinflammation and Alzheimer’s disease.”Cells11 (2022): 1885.

   Google Scholar, Crossref, Indexed at